1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: US Biotechnology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. US Biotechnology Market, by Technology Type
8.1.1. Fermentation
8.1.1.1. Market Revenue and Forecast
8.1.2. Tissue Engineering and Regeneration
8.1.2.1. Market Revenue and Forecast
8.1.3. Polymerase Chain Reaction (PCR) Technology
8.1.3.1. Market Revenue and Forecast
8.1.4. Nanobiotechnology
8.1.4.1. Market Revenue and Forecast
8.1.5. Chromatography
8.1.5.1. Market Revenue and Forecast
8.1.6. Deoxyribonucleic Acid (DNA) Sequencing
8.1.6.1. Market Revenue and Forecast
8.1.7. Cell Based Assay
8.1.7.1. Market Revenue and Forecast
9.1. US Biotechnology Market, by Application
9.1.1. Bio-pharmacy
9.1.1.1. Market Revenue and Forecast
9.1.2. Bio-industries
9.1.2.1. Market Revenue and Forecast
9.1.3. Bio-services
9.1.3.1. Market Revenue and Forecast
9.1.4. Bio-agriculture
9.1.4.1. Market Revenue and Forecast
9.1.5. Bio-informatics
9.1.5.1. Market Revenue and Forecast
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Technology
10.1.3.2. Market Revenue and Forecast, by Application
11.1. Lonza
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. AstraZeneca
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Pfizer Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Gilead Sciences Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmann-La Roche Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Biogen
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. CELGENE Corporation
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Sanofi
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Abbott
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Novartis AG
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
